Marinus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MRNS Marinus Pharmaceuticals Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
ASML ASML Holding NV
FUN Cedar Fair LP
NWFFX American Funds New World Fund® Class F-1
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Closing Price
$3.46
Day's Change
0.245 (7.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.69
Day's Low
3.11
Volume
(Light)
Volume:
7,745,758

10-day average volume:
17,586,442
7,745,758

Display:

Providers:

UpdateCancel
6 providers
September 15, 2020
Thinking about buying stock in Marinus Pharmaceuticals, Fiat Chrysler, Lithium Americas, Xeris Pharmaceuticals, or Nokia?

InvestorsObserver issues critical PriceWatch Alerts for MRNS, FCAU, LAC, XERS, and NOK. https://mma.prnewswire.com/media/1086590/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

September 14, 2020
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial...(BusinessWire)

Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has entered into a five-year development contract with the Biomedical...(BusinessWire)

September 08, 2020
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at the Morgan Stanley Virtual Global...(BusinessWire)

August 11, 2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the "Company" or "Marinus"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to seven new...(BusinessWire)

August 06, 2020
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical development activities and reported its...(BusinessWire)

July 30, 2020
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare...(BusinessWire)

July 29, 2020
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Charles ("Chuck") Austin to its Board of Directors. (BusinessWire)

June 30, 2020
Marinus Pharmaceuticals Provides Pipeline Update

-- CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020 -- First patient enrolled in Phase 2 Tuberous Sclerosis Complex trial -- Enrollment in PCDH19 proof-of-concept trial increases to 25-30 patients (Globe Newswire)

June 25, 2020
Research Uncovers New Role Psychedelics Could Play in Therapy

The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases and it operates in one of the most diverse and complex markets. The pharmaceutical market is also expected to grow in the coming years, despite the recent growth...(PR Newswire)

June 24, 2020
Marinus Pharmaceuticals to Host Pipeline Update Webinar

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial...(Globe Newswire)

June 22, 2020
Marinus Pharmaceuticals to Present at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink's CybeRx Series: 2 Annual...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.